131 related articles for article (PubMed ID: 34115181)
1. The fetal outcomes after neoadjuvant platinum and paclitaxel chemotherapy during pregnancy: analysis of three cases and review of the literature.
Wang M; Yin Z; Miao J; Wu Y
Arch Gynecol Obstet; 2022 Jan; 305(1):49-54. PubMed ID: 34115181
[TBL] [Abstract][Full Text] [Related]
2. Efficacy of neoadjuvant platinum-based chemotherapy during the second and third trimester of pregnancy in women with cervical cancer: an updated systematic review and meta-analysis.
Song Y; Liu Y; Lin M; Sheng B; Zhu X
Drug Des Devel Ther; 2019; 13():79-102. PubMed ID: 30587930
[TBL] [Abstract][Full Text] [Related]
3. Taxanes in combination with platinum derivatives for the treatment of ovarian cancer during pregnancy: A literature review
.
Zheng X; Zhu Y; Zhao Y; Feng S; Zheng C
Int J Clin Pharmacol Ther; 2017 Sep; 55(9):753-760. PubMed ID: 28737125
[TBL] [Abstract][Full Text] [Related]
4. Incidence of childhood hearing loss after in utero exposure to platinum agents.
Finch LE; Cardonick EH
Prenat Diagn; 2021 Oct; 41(11):1467-1474. PubMed ID: 34462927
[TBL] [Abstract][Full Text] [Related]
5. Neoadjuvant chemotherapy with paclitaxel plus platinum followed by radical surgery in early cervical cancer during pregnancy: three case reports.
Chun KC; Kim DY; Kim JH; Kim YM; Kim YT; Nam JH
Jpn J Clin Oncol; 2010 Jul; 40(7):694-8. PubMed ID: 20427545
[TBL] [Abstract][Full Text] [Related]
6. Bevacizumab and paclitaxel-carboplatin chemotherapy and secondary cytoreduction in recurrent, platinum-sensitive ovarian cancer (NRG Oncology/Gynecologic Oncology Group study GOG-0213): a multicentre, open-label, randomised, phase 3 trial.
Coleman RL; Brady MF; Herzog TJ; Sabbatini P; Armstrong DK; Walker JL; Kim BG; Fujiwara K; Tewari KS; O'Malley DM; Davidson SA; Rubin SC; DiSilvestro P; Basen-Engquist K; Huang H; Chan JK; Spirtos NM; Ashfaq R; Mannel RS
Lancet Oncol; 2017 Jun; 18(6):779-791. PubMed ID: 28438473
[TBL] [Abstract][Full Text] [Related]
7. A systematic overview of chemotherapy effects in ovarian cancer.
Högberg T; Glimelius B; Nygren P;
Acta Oncol; 2001; 40(2-3):340-60. PubMed ID: 11441940
[TBL] [Abstract][Full Text] [Related]
8. Paclitaxel use in pregnancy: neonatal follow-up of infants with positive detection of intact paclitaxel and metabolites in meconium at birth.
Cardonick EH; O'Laughlin AE; So SC; Fleischer LT; Akoto S
Eur J Pediatr; 2022 Apr; 181(4):1763-1766. PubMed ID: 35066626
[TBL] [Abstract][Full Text] [Related]
9. Infant outcome after active management of early-onset fetal growth restriction with absent or reversed umbilical artery blood flow.
Morsing E; Brodszki J; Thuring A; Maršál K
Ultrasound Obstet Gynecol; 2021 Jun; 57(6):931-941. PubMed ID: 32862450
[TBL] [Abstract][Full Text] [Related]
10. Neoadjuvant chemotherapy with paclitaxel plus platinum for invasive cervical cancer in pregnancy: two case report and literature review.
Li J; Wang LJ; Zhang BZ; Peng YP; Lin ZQ
Arch Gynecol Obstet; 2011 Sep; 284(3):779-83. PubMed ID: 21691768
[TBL] [Abstract][Full Text] [Related]
11. Carboplatin-based doublet plus bevacizumab beyond progression versus carboplatin-based doublet alone in patients with platinum-sensitive ovarian cancer: a randomised, phase 3 trial.
Pignata S; Lorusso D; Joly F; Gallo C; Colombo N; Sessa C; Bamias A; Salutari V; Selle F; Frezzini S; De Giorgi U; Pautier P; Bologna A; Orditura M; Dubot C; Gadducci A; Mammoliti S; Ray-Coquard I; Zafarana E; Breda E; Favier L; Ardizzoia A; Cinieri S; Largillier R; Sambataro D; Guardiola E; Lauria R; Pisano C; Raspagliesi F; Scambia G; Daniele G; Perrone F;
Lancet Oncol; 2021 Feb; 22(2):267-276. PubMed ID: 33539744
[TBL] [Abstract][Full Text] [Related]
12. Olaparib combined with chemotherapy for recurrent platinum-sensitive ovarian cancer: a randomised phase 2 trial.
Oza AM; Cibula D; Benzaquen AO; Poole C; Mathijssen RH; Sonke GS; Colombo N; Špaček J; Vuylsteke P; Hirte H; Mahner S; Plante M; Schmalfeldt B; Mackay H; Rowbottom J; Lowe ES; Dougherty B; Barrett JC; Friedlander M
Lancet Oncol; 2015 Jan; 16(1):87-97. PubMed ID: 25481791
[TBL] [Abstract][Full Text] [Related]
13. Secondary cytoreduction followed by chemotherapy versus chemotherapy alone in platinum-sensitive relapsed ovarian cancer (SOC-1): a multicentre, open-label, randomised, phase 3 trial.
Shi T; Zhu J; Feng Y; Tu D; Zhang Y; Zhang P; Jia H; Huang X; Cai Y; Yin S; Jiang R; Tian W; Gao W; Liu J; Yang H; Cheng X; Zang R
Lancet Oncol; 2021 Apr; 22(4):439-449. PubMed ID: 33705695
[TBL] [Abstract][Full Text] [Related]
14. Perinatal outcomes of a pregnancy complicated by cancer, including neonatal follow-up after in utero exposure to chemotherapy: results of an international registry.
Cardonick E; Usmani A; Ghaffar S
Am J Clin Oncol; 2010 Jun; 33(3):221-8. PubMed ID: 19745695
[TBL] [Abstract][Full Text] [Related]
15. Paclitaxel plus platinum-based chemotherapy versus conventional platinum-based chemotherapy in women with relapsed ovarian cancer: the ICON4/AGO-OVAR-2.2 trial.
Parmar MK; Ledermann JA; Colombo N; du Bois A; Delaloye JF; Kristensen GB; Wheeler S; Swart AM; Qian W; Torri V; Floriani I; Jayson G; Lamont A; Tropé C;
Lancet; 2003 Jun; 361(9375):2099-106. PubMed ID: 12826431
[TBL] [Abstract][Full Text] [Related]
16. Improved outcomes with dose-dense paclitaxel-based neoadjuvant chemotherapy in advanced epithelial ovarian carcinoma.
Becker DA; Thomas ED; Gilbert AL; Boone JD; Straughn JM; Huh WK; Bevis KS; Leath CA; Alvarez RD
Gynecol Oncol; 2016 Jul; 142(1):25-29. PubMed ID: 27130405
[TBL] [Abstract][Full Text] [Related]
17. Association between in vitro platinum resistance in the EDR assay and clinical outcomes for ovarian cancer patients.
Holloway RW; Mehta RS; Finkler NJ; Li KT; McLaren CE; Parker RJ; Fruehauf JP
Gynecol Oncol; 2002 Oct; 87(1):8-16. PubMed ID: 12468336
[TBL] [Abstract][Full Text] [Related]
18. [Clinical analysis of hypersensitivity reaction of platinum in ovarian cancer and cervical cancer patients].
Li L; Wu M; Yang JX; Wan XR; Huang HF; Pan LY; Shen K; Lang JH; Xiang Y
Zhonghua Fu Chan Ke Za Zhi; 2016 Nov; 51(11):825-831. PubMed ID: 27916065
[No Abstract] [Full Text] [Related]
19. Optimal chemotherapy treatment for women with recurrent ovarian cancer.
Fung-Kee-Fung M; Oliver T; Elit L; Oza A; Hirte HW; Bryson P
Curr Oncol; 2007 Oct; 14(5):195-208. PubMed ID: 17938703
[TBL] [Abstract][Full Text] [Related]
20. A pilot study of three-cycle consolidation chemotherapy with paclitaxel and platinum in epithelial ovarian cancer patients with clinical complete response after paclitaxel and platinum chemotherapy.
Lee SJ; Lee JW; Min JA; Park CS; Kim BG; Lee JH; Bae DS
Int J Gynecol Cancer; 2006; 16(1):95-100. PubMed ID: 16445617
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
